Thyroid Function Testing in the Diagnosis and Monitoring of Thyroid Function Disorder

Effective Date: October 24, 2018

Scope

This guideline outlines testing for thyroid dysfunction in patients (pediatric and adult), including pregnant women or women planning pregnancy, and the monitoring of patients treated for primary thyroid function disorders. It does not apply to the BC Newborn Screening Program. This guideline outlines testing for thyroid stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3) and anti-thyroid peroxidase (TPO).

Information on other tests, including thyroglobulin/antithyroglobulin (Tg/anti Tg) and antibodies to the thyroid stimulating hormone receptor (TRAb), are covered in the associated BC Guideline *Hormone Testing – Indications and Appropriate Use*.

Key Recommendations

- Routine thyroid function testing is not recommended in asymptomatic patients (outside of the BC Newborn Screening Program). Testing may be indicated when non-specific symptoms or signs are present in patients at risk for thyroid disease.
- A TSH value within the laboratory reference interval excludes the majority of cases of primary thyroid dysfunction.
- If initial TSH testing is normal, repeat testing is unnecessary unless there is a change in clinical condition.
- Measurement of fT3 is rarely indicated in suspected thyroid disease.
- Screening for undiagnosed hyperthyroidism or hypothyroidism should not be performed in hospitalized patients or during acute illness unless hyperthyroidism or hypothyroidism is the suspected cause of the clinical presentation or represents a significant co-morbidity.
- If a woman is pregnant or planning pregnancy, TSH testing is indicated if she has specific risk factors (see Table 3).

Indications for Testing

Routine thyroid function testing is not recommended in asymptomatic patients (outside of the BC Newborn Screening Program). Testing may be indicated when non-specific symptoms or signs are present in patients who have specific risk factors for thyroid disease. Testing is indicated for patients with a clinical presentation consistent with thyroid disease as delineated in Table 1: Symptoms and Signs of Thyroid Disease below.

Where thyroid testing in an asymptomatic patient has occurred and the patient has been diagnosed with subclinical thyroid disease, see the Subclinical Thyroid Disease section.

If initial testing is normal, repeat testing is unnecessary unless there is a change in clinical condition.

Risk Factors

Risk factors for thyroid disease include:
- men: age ≥ 60 years;
- women: age ≥ 50 years;
- personal history or strong family history of thyroid disease;
• diagnosis of other autoimmune diseases;
• past history of neck irradiation;
• previous thyroidectomy or radioactive iodine ablation;
• drug therapies such as lithium and amiodarone;
• dietary factors (iodine excess and iodine deficiency in patients from developing countries); or
• certain chromosomal or genetic disorders (e.g., Turner syndrome, Down syndrome and mitochondrial disease).

For risk factors during pregnancy, see Table 3 in the Thyroid Disease in Pregnancy section below.

### Signs and Symptoms

#### Table 1: Symptoms and Signs of Thyroid Disease

This table reflects common manifestations of thyroid disease in adults. Pediatric-specific manifestations of hypothyroidism (e.g., slow growth and delayed osseous maturation, delayed puberty or precocious puberty in severe longstanding hypothyroidism) or hyperthyroidism (e.g., difficulty gaining weight, growth acceleration, advanced bone age or delayed puberty) should also be considered in the pediatric context.

<table>
<thead>
<tr>
<th></th>
<th>Hypothyroidism: Symptoms and Signs</th>
<th>Hyperthyroidism: Symptoms and Signs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neuropsychiatric</strong></td>
<td>• Depression</td>
<td>• Anxiety, irritability, restlessness</td>
</tr>
<tr>
<td></td>
<td>• Decreased mental function</td>
<td>• Fatigue, restless sleep</td>
</tr>
<tr>
<td></td>
<td>• Decreased attention span</td>
<td>• Increased appetite</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Decreased attention span</td>
</tr>
<tr>
<td><strong>Neuromuscular</strong></td>
<td>• Physical tiredness</td>
<td>• Tremors</td>
</tr>
<tr>
<td></td>
<td>• Paresthesia</td>
<td>• Proximal muscle weakness</td>
</tr>
<tr>
<td></td>
<td>• Hypokinesis</td>
<td>• Hyporeflexia</td>
</tr>
<tr>
<td></td>
<td>• Hyporeflexia</td>
<td></td>
</tr>
<tr>
<td><strong>Physical Appearance/Voice</strong></td>
<td>• Weight gain&lt;sup&gt;A&lt;/sup&gt;</td>
<td>• Weight loss</td>
</tr>
<tr>
<td></td>
<td>• Coarse, dry skin</td>
<td>• Hair loss</td>
</tr>
<tr>
<td></td>
<td>• Periorbital edema</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Hoarseness</td>
<td></td>
</tr>
<tr>
<td><strong>Cardiovascular</strong></td>
<td>• Bradycardia</td>
<td>• Palpitations, tachycardia</td>
</tr>
<tr>
<td></td>
<td>• Isolated diastolic hypertension</td>
<td>• Atrial fibrillation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Isolated systolic hypertension</td>
</tr>
<tr>
<td><strong>Thyroid Gland</strong></td>
<td>• Goitre</td>
<td>• Goitre</td>
</tr>
<tr>
<td><strong>Thermoregulation</strong></td>
<td>• Diminished sweating</td>
<td>• Increased sweating</td>
</tr>
<tr>
<td></td>
<td>• Cold intolerance</td>
<td>• Heat intolerance</td>
</tr>
<tr>
<td><strong>Ophthalmologic</strong></td>
<td></td>
<td>• Blurred or double vision</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Dry eyes, conjunctivitis, proptosis or dysconjugate gaze</td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td>• Constipation</td>
<td>• Increased frequency of stools</td>
</tr>
<tr>
<td><strong>Pituitary Function</strong></td>
<td>• Menorrhagia</td>
<td>• Amenorrhea/oligomenorrhea</td>
</tr>
</tbody>
</table>

<sup>A</sup> Hypothyroidism rarely causes weight gain in pediatric populations.
Tests

- **Thyroid Stimulating Hormone (TSH)**

  Measurement of TSH is the principal test for the evaluation of thyroid function in the vast majority of circumstances provided there is no clinical or historical evidence to suggest damage or disease of the hypothalamic-pituitary axis. Hypothalamic and pituitary disease can cause central hypothyroidism, which is rare. Central hypothyroidism can be caused by invasive or compressive lesions, iatrogenic factors, injuries, vascular accidents, autoimmune disease, infiltrative disease, congenital conditions and infections. If central hypothyroidism is being investigated “suspicion of pituitary insufficiency” should be included as a clinical indication and a request for fT4 (with or without TSH) should be indicated in the space provided on the standard out-patient laboratory requisition (see Appendix 1: BC Laboratory Algorithm for Thyroid Tests).

  **A TSH value within the laboratory reference interval excludes the majority of cases of primary thyroid dysfunction.** The TSH reference interval will vary depending on the testing laboratory. Laboratories in BC retain specimens for 2 to 7 days in case add-on testing is required (see Appendix 1: BC Laboratory Algorithm for Thyroid Tests).

  - If “suspected hyperthyroidism” is chosen on the standard out-patient laboratory requisition, the laboratory will perform the TSH test first and then automatically perform the fT4 and fT3 if required.
  - If “suspected hypothyroidism” is chosen on the standard out-patient laboratory requisition, the laboratory will perform the TSH test first and then automatically perform the fT4 if required.
  - If free thyroid hormones are ordered without TSH, a clinical indication is required.

  See Figure 1 for a Clinical Algorithm of Thyroid Function Tests for Diagnosis and Monitoring in Symptomatic Non-Pregnant Patients and Table 2 for Potential Causes of Abnormal Hormone Levels.

- **Free Thyroxine (fT4) and Free Triiodothyronine (fT3)**

  Measurements of fT4 and fT3 have replaced those of total T4 and total T3 levels. Laboratories are permitted to substitute free hormone assays when total T3 or T4 have been ordered.

  **Measurement of fT3 is rarely indicated in suspected thyroid disease.** This is reserved for situations where thyroid disease is suspected clinically and TSH is abnormal, but fT4 is inappropriately normal.

- **Anti-Thyroid Peroxidase (TPO)**

  Anti-TPO measurement is not routinely indicated in patients with hypothyroidism as it does not generally change clinical management. In specific circumstances it may be helpful in further clinical decision making. In patients with a goitre or mildly elevated TSH, anti-TPO measurement is used to evaluate whether the cause is autoimmune thyroiditis. TPO antibody positivity increases the risk of developing hypothyroidism in patients with subclinical hypothyroidism, autoimmune diseases (e.g., type 1 diabetes), chromosomal disorders (e.g., Turner syndrome and Down syndrome) or patients who are on certain drug therapies (e.g., lithium, amiodarone) or are pregnant or postpartum (see Thyroid Disease in Pregnancy section below). Once a patient is known to be TPO antibody positive, repeat analysis is not indicated.

  There are other thyroid antibody tests with specific indications which are not covered in this guideline and are discussed in the associated BC Guideline Hormone Testing – Indications and Appropriate Use.

- **Follow-Up Testing**

  In most cases, ordering a different test is more useful than repeating the same test (e.g., if a patient has specific clinical findings and a TSH result does not appear to correlate with the patient’s clinical status, it may be more appropriate to follow with an fT4 measurement). If fT4 is being ordered to investigate or follow central hypothyroidism, “suspicion of pituitary insufficiency” should be included as a clinical indication and a request for fT4 (with or without TSH) should be written in the space provided on the standard out-patient laboratory requisition.

  Consultation with a lab physician or an endocrinologist is recommended when the test result is in conflict with the clinical presentation so that investigation for analytical interferences or rare conditions can be undertaken.

  Note that thyroid ultrasound scan is not routinely recommended in patients with abnormal thyroid function tests, unless there is a palpable abnormality of the thyroid gland (Choosing Wisely Endocrinology and Metabolism Recommendation). See the associated BC Guideline Ultrasound Prioritization.
Figure 1: Clinical Algorithm for Thyroid Function Tests for Diagnosis and Monitoring in Symptomatic Non-Pregnant Patients.

This algorithm only applies to patients with an intact hypothalamic-pituitary axis and does not apply to hospitalized patients (Sick Euthyroid Syndrome). For information during pregnancy, see the Thyroid Disease in Pregnancy section. For laboratory testing procedures, see Appendix 1: BC Laboratory Algorithm for Thyroid Tests.

Notes:
A. TSH reference intervals may vary depending on the testing lab.
B. Overt primary hypothyroidism is diagnosed when the TSH is elevated and the fT4 is low. A decision to treat is often made if the TSH is >10 mU/L even if the fT4 is within the reference range.
C. An abnormal TSH level, associated with a normal fT4 and fT3 level is most often due to subclinical thyroid dysfunction. Rarely, it may be related to a lab artefact such as antibody interference.
### Table 2. Potential Causes of Abnormal Hormone Levels (TSH, fT4 and fT3)

<table>
<thead>
<tr>
<th>Causes of High TSH&lt;sup&gt;15–17&lt;/sup&gt;</th>
<th>Laboratory Result</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypothyroidism</td>
<td>TSH ↑, fT4 ↓&lt;sup&gt;6&lt;/sup&gt;</td>
<td>See Monitoring: Hypothyroidism or Thyroid Disease in Pregnancy</td>
</tr>
<tr>
<td>• Autoimmune</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subclinical hypothyroidism</td>
<td>TSH ↑ (usually less than 10 mU/L),&lt;sup&gt;4&lt;/sup&gt; fT4 normal&lt;sup&gt;13,18&lt;/sup&gt; (fT3 not indicated)</td>
<td>See Subclinical Hypothyroidism or Thyroid Disease in Pregnancy</td>
</tr>
<tr>
<td>• Typically asymptomatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Assay artefact&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recovery from non-thyroidal illness</td>
<td>Testing not usually indicated</td>
<td>See Sick Euthyroid Syndrome</td>
</tr>
<tr>
<td>• Sick Euthyroid Syndrome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very rare causes</td>
<td>TSH ↑ (or normal), fT4 ↑&lt;sup&gt;15,16&lt;/sup&gt;</td>
<td>See Monitoring: Hypothalamic or Pituitary Disease</td>
</tr>
<tr>
<td>• Pituitary disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Resistance to thyroid hormone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Assay artefact&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Causes of Low TSH<sup>15–17</sup>

<table>
<thead>
<tr>
<th>Causes of Low TSH&lt;sup&gt;15–17&lt;/sup&gt;</th>
<th>Laboratory Result</th>
<th>Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperthyroidism or other causes of thyrotoxicosis</td>
<td>TSH ↓, fT4 ↑&lt;sup&gt;6&lt;/sup&gt; (fT3 not indicated)</td>
<td>See Monitoring: Hyperthyroidism See Thyroid Disease in Pregnancy</td>
</tr>
<tr>
<td>• Excessive thyroid hormone replacement (levothyroxine)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Graves' disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Subacute thyroiditis (viral)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Painless/postpartum thyroiditis (autoimmune)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Toxic (multinodular) goitre</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperthyroidism or other causes of thyrotoxicosis</td>
<td>TSH ↓, fT4 normal/low, fT3 ↑&lt;sup&gt;6&lt;/sup&gt;</td>
<td>See Monitoring: Hyperthyroidism See Thyroid Disease in Pregnancy</td>
</tr>
<tr>
<td>• T3 thyrotoxicosis (e.g., autonomous nodule)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Excessive thyroid hormone replacement (liothyronine or desiccated thyroid)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subclinical hyperthyroidism</td>
<td>TSH ↓&lt;sup&gt;4&lt;/sup&gt;, fT4 normal, fT3 normal&lt;sup&gt;21&lt;/sup&gt;</td>
<td>See Subclinical Hyperthyroidism See Thyroid Disease in Pregnancy</td>
</tr>
<tr>
<td>• Recovery of hyperthyroidism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Pregnancy related&lt;sup&gt;14,20&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Assay artefact&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sick Euthyroid Syndrome</td>
<td>Testing not usually indicated</td>
<td>See Sick Euthyroid Syndrome</td>
</tr>
<tr>
<td>• Hospitalized patients, recovery from severe illness</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very rare causes</td>
<td>TSH normal (or ↓), fT4 ↓&lt;sup&gt;6&lt;/sup&gt;</td>
<td>See Monitoring: Hypothalamic or Pituitary Disease</td>
</tr>
<tr>
<td>• Central hypothyroidism (hypopituitarism)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Assay artefact&lt;sup&gt;8&lt;/sup&gt;</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A. Treatment is considered when TSH is above 10 mU/L<sup>18</sup> for subclinical hypothyroidism or below 0.1 mU/L<sup>21</sup> for subclinical hyperthyroidism.

B. Assay artefact may cause abnormal laboratory results. Immunoassays for thyroid function tests are subject to analytical interference due to heterophile antibodies<sup>22</sup>, variant TSH isoforms by glycosylation<sup>22</sup>, macro TSH (TSH in combination with IgG antibody)<sup>22</sup>, or high dose biotin administration<sup>23</sup>. If an assay artefact is suspected, consult with a lab physician.
Monitoring of Thyroid Disease

- **Hypothyroidism**
  Since TSH values change slowly,24 frequent repeat testing is not indicated. TSH may be repeated after at least 6 weeks following a change in thyroid hormone replacement dose or in a patient's clinical status.13 Care should be taken not to overtreat with levothyroxine, as it can result in atrial fibrillation (more commonly in the elderly) and bone loss in postmenopausal women.13

  Once TSH has normalized with treatment, it should be checked annually unless a new indication arises. This confirms adequacy of treatment dose and compliance with therapy.

  Note that even within the reference interval, TSH levels in the same individual can vary by 50% when measured at different times of day, with lowest values in the late afternoon and highest values at midnight.25 In individuals with subclinical hypothyroidism, TSH values can vary by up to 40% even when measured at the same time on different days without indicating a change in thyroid function.26 As long as TSH remains within the reference interval, changes over time are not important.

  Patients taking lithium and amiodarone are at increased risk for hypothyroidism13 and monitoring of TSH is recommended every 6 months. Amiodarone treatment may also lead to amiodarone-induced thyrotoxicosis and monitoring is recommended every 3–6 months.21

- **Hyperthyroidism**
  To monitor patients on treatment for Graves' disease or other causes of hyperthyroidism, allow at least one month or longer before repeating fT4 and TSH levels since pituitary secretion of TSH may be suppressed for protracted periods following hyperthyroidism.21 Until TSH suppression resolves, initial treatment and dosing decisions should be based on fT4, or in the case of T3 thyrotoxicosis, on fT3.21

  Patients taking amiodarone are at increased risk of amiodarone-induced thyrotoxicosis and monitoring is recommended every 3–6 months.21

- **Hypothalamic or Pituitary Disease**
  TSH is only useful as a measure of thyroid disease if the hypothalamic-pituitary-thyroid axis is intact. When pituitary or hypothalamic disease is suspected, fT4 measurement is required to make the diagnosis or assess adequacy of thyroid replacement therapy.11, 12

Subclinical Thyroid Disease

Subclinical thyroid disease is a biochemical diagnosis and typically has either no symptoms or non-specific symptoms, is more common in women, and prevalence increases with advanced age.18, 21

- **Subclinical Hypothyroidism**
  In subclinical hypothyroidism, TSH is elevated in the presence of normal levels of fT4 (see Table 2).13, 18

  **Treatment for subclinical hypothyroidism is recommended when TSH rises above 10 mU/L.**18 Treatment can be considered when TSH is between the upper limit of the reference interval but ≤10 mU/L and any of the following are present:13
  - symptoms suggestive of hypothyroidism;
  - elevated TPO antibodies;
  - evidence of atherosclerotic cardiovascular disease, heart failure, or associated risk factors for these diseases; or
  - pregnancy (see Thyroid Disease in Pregnancy section below).
The prevalence of subclinical hypothyroidism in the general population is between 4.3–8.5%. Every year, 2.6% of subclinical hypothyroidism patients without elevated TPO antibodies and 4.3% of subclinical hypothyroidism patients with elevated TPO antibodies progress to overt hypothyroidism.

**Monitoring of TSH in untreated patients with subclinical hypothyroidism is indicated at 6–12 month intervals, or sooner if the clinical situation changes.**

**Subclinical Hyperthyroidism**

In subclinical hyperthyroidism, the TSH is suppressed in the presence of normal levels of fT4 (see Table 2). Subclinical hyperthyroidism is less common, with a prevalence of 0.7%.

Patients with atrial fibrillation or osteoporosis should be screened for hyperthyroidism. In patients over age 60 with TSH < 0.1 mU/L but with a normal fT4, the relative risk for atrial fibrillation increases threefold. Post-menopausal women with subclinical hyperthyroidism may have an increased rate of bone loss. In the elderly, there is a higher cardiovascular risk and an increased risk of fracture. **Treatment of subclinical hyperthyroidism should be considered in the elderly.**

Patients with subclinical hyperthyroidism due to multi-nodular goitre or toxic adenoma are unlikely to normalize and are therefore more likely to benefit from treatment.

**Sick Euthyroid Syndrome**

In Sick Euthyroid Syndrome (Non-Thyroidal Illness Syndrome), the hypothalamic-pituitary-thyroid axis is affected by a non-thyroid illness. It occurs in patients without a previously diagnosed thyroid disease.

Almost any condition that can make a person ill can cause Sick Euthyroid Syndrome and the elderly are more susceptible because of multiple co-morbid conditions. The syndrome is acute and spontaneously reverses and occurs commonly after surgery, during fasting, during many acute febrile illnesses, and after acute myocardial infarction. Malnutrition, renal and cardiac failure, hepatic diseases, uncontrolled diabetes, cerebrovascular diseases, and malignancy can also produce abnormalities in thyroid function tests.

**Testing**

Ideally, thyroid function tests should not be performed in hospitalized patients unless hyperthyroidism or hypothyroidism is the suspected cause of the clinical presentation or represents a significant co-morbidity. However, where thyroid testing has occurred, any abnormal results should be interpreted with caution and with a realization that Sick Euthyroid Syndrome is the most likely explanation for the finding if performed in hospitalized patients rather than true thyroid disease.

Multiple patterns of hormone levels are possible (see Table 2); abnormalities fluctuate during the course of illness and recovery. However, usually fT3 is low, fT4 is low in some sicker patients, and TSH is low or normal. As patients recover from their illness, TSH may normalize or become elevated.

TSH levels must be interpreted with caution in hospitalized individuals. However, values below < 0.1 mU/L or > 20 mU/L merit a consultation with endocrinology or internal medicine. Levothyroxine replacement has not been shown to be beneficial and should not be used in patients with Sick Euthyroid Syndrome.

**Thyroid Disease in Pregnancy**

Currently, there is insufficient evidence to advocate for universal screening (see Universal Screening During Pregnancy in the Controversies in Care Section below). Based on the 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum, if a woman is pregnant or planning pregnancy, TSH testing is indicated if she has any of the risk factors listed in Table 3. Pregnant women often experience symptoms that can be non-specific or vague and as such, it may be difficult to distinguish between symptoms of thyroid dysfunction and normal changes of pregnancy. Clinicians should have a low threshold for TSH testing in pregnancy.
Table 3. Risk Factors for Thyroid Disease in Women who are Pregnant or Anticipating Becoming Pregnant

- age > 30 years
- more than 2 prior pregnancies
- history of pregnancy loss, preterm delivery, or infertility
- type 1 diabetes or other autoimmune disorders
- morbid obesity (BMI ≥ 40 kg/m²)
- history of hypothyroidism/hyperthyroidism or current symptoms or signs of thyroid dysfunction
- family history of autoimmune thyroid disease or thyroid dysfunction (1st degree relative)
- history of head or neck radiation or prior thyroid surgery
- known TPO antibody positivity or presence of a goitre
- currently receiving levothyroxine replacement
- use of amiodarone or lithium, or recent administration of iodinated radiologic contrast
- residing (or recently resided) in an area of known moderate to severe iodine insufficiency

Hypothyroidism in Pregnancy and Postpartum

Research data support a possible connection between untreated overt maternal hypothyroidism and neuropsychological impairment in the offspring. If hypothyroidism has been diagnosed before or during pregnancy, treatment should be adjusted to achieve a TSH level within the normal trimester specific reference interval.

First trimester reference intervals, in particular, are less than the normal population reference interval. Laboratories in BC should report trimester specific reference intervals as an appended comment on all women of child bearing age. Treatment should be initiated for women whose TSH is above the trimester specific upper limit of normal as reported by the laboratory (see Treatment of Women with Subclinical Hypothyroidism in the Controversies in Care Section below).

A preconception TSH between the lower reference limit and 2.5 mU/L is recommended in women being actively treated for hypothyroidism.

In women with overt and subclinical hypothyroidism (treated or untreated) and women at risk for hypothyroidism (euthyroid patients who are TPO antibody positive, post-hemithyroidectomy or treated with radioactive iodine), TSH should be measured every 4–6 weeks until midgestation and at least once near 30 weeks gestation.

In women being treated for hypothyroidism, levothyroxine replacement dosage may need to increase by 25–50% during pregnancy, particularly in the first trimester. After starting thyroid hormone replacement or a dose change during pregnancy, TSH should be remeasured every 4–6 weeks.

Postpartum

After delivery, most women treated for hypothyroidism will need a decrease in the levothyroxine dose that they received during pregnancy. TSH should be evaluated 6 weeks after the dose change.

Hyperthyroidism in Pregnancy and Postpartum

Hyperthyroid patients should have appropriate specialist consultation (endocrinologist or maternal-fetal medicine (e.g., obstetric internal medicine)) when contemplating pregnancy or during pregnancy.

In the course of a normal pregnancy, TSH may be low in the first trimester, when human chorionic gonadotropin (hCG) peaks. Pathological causes of low TSH in pregnancy may include multiple gestation, hyperemesis gravidarum and molar pregnancy.

In this context, a normal fT4 generally excludes hyperthyroidism. After hCG mediated hyperthyroidism, the most common pathological cause of hyperthyroidism in pregnancy is autoimmune Grave’s disease. Toxic multinodular goitre and toxic adenoma are less common than autoimmune causes.

During pregnancy, if TSH is low, repeat the TSH along with fT4 (using laboratory reported pregnancy specific reference intervals). If TSH is still low and fT4 is high, refer to a specialist in endocrinology or maternal-fetal medicine (e.g., obstetric internal medicine). If TSH is still low but fT4 is normal, repeat testing in 4 weeks is suggested. If TSH is still low referral to a specialist is recommended.
Postpartum
Because of changes in the modulation of the immune system, there is an increased risk of thyroiditis and new presentation or relapse of Graves’ disease in the postpartum period. One study found that hyperthyroidism diagnosed within 3 months of delivery was most often caused by postpartum thyroiditis while hyperthyroidism diagnosed after 6.5 months was caused by Graves’ disease.

If a patient is persistently hyperthyroid postpartum, referral to an appropriate specialist in endocrinology or maternal-fetal medicine (e.g., obstetric internal medicine) is recommended.

Postpartum Thyroiditis
Postpartum thyroiditis is an autoimmune disorder and the presence of anti-TPO antibodies increases the risk of disease. This condition occurs in approximately 5% of women in the first year postpartum.

Postpartum thyroiditis is often mild and transient. There is insufficient evidence to recommend screening all women for postpartum thyroiditis. Women previously known to be TPO antibody positive should have a TSH performed at 3 and 6 months postpartum or as clinically indicated. The disorder may present as hyperthyroidism followed by hypothyroidism and subsequent recovery of normal thyroid function. Some women may present with hypothyroidism without a hyperthyroid interval and may remain hypothyroid. Up to 10–50% of the women who have had postpartum thyroiditis will go on to develop permanent primary hypothyroidism after a postpartum thyroiditis episode.

An annual TSH is recommended in patients with a history of postpartum thyroiditis. There is a significant risk for recurrent postpartum thyroiditis in subsequent pregnancies.

Controversies in Care

Controversies in Care: Universal Screening During Pregnancy
There is clear evidence that treating a pregnant woman known to be hypothyroid has important benefits. Treatment reduces adverse pregnancy outcomes including preterm delivery or miscarriage and neuropsychological impairment of the offspring is associated with hypothyroidism. At one time, studies suggested that failure to detect even subclinical hypothyroidism might have similar consequences. This led some groups to recommend that every woman be screened. Subsequent better designed studies have not confirmed these concerns. In fact, harm could occur when pregnant women are overtreated. If a woman has risk factors, TSH testing is specifically recommended in early pregnancy (see the section on Thyroid Disease in Pregnancy). In a woman without symptoms and without risk factors, testing is discretionary.

Controversies in Care: Treatment of Pregnant Women with Subclinical Hypothyroidism
Although there is no strong evidence to support routinely measuring TPO antibodies in pregnant women, the American Thyroid Association recommends that treatment may be initiated at lower TSH levels in women known to be TPO antibody positive. If the TSH value is above 2.5 mU/L but within the reference interval, some practitioners would consider treating if the TPO antibody is positive.

Resources

Practitioner Resources

  A telephone consultation line for select specialty services for physicians, nurse practitioners and medical residents. If the relevant specialty area is available through your local RACE line, please contact them first. Contact your local RACE line for the list of available specialty areas. If your local RACE line does not cover the relevant specialty service or there is no local RACE line in your area, or to access Provincial Services, please contact the Vancouver Coastal Health Region/Providence Health Care RACE line.
  - Vancouver Coastal Health Region/Providence Health Care: www.raceconnect.ca
    Available Monday to Friday, 8 am to 5 pm at 604-696-2131 (Vancouver area) or 1-877-696-2131 (toll free)
  - Northern RACE: 1-877-605-7223 (toll free)
    1-844-365-7223 (toll free)
References


Abbreviations

fT4 Free thyroxine
fT3 Free triiodothyronine
hCG human chorionic gonadotropin
TPO Thyroid peroxidase
TSH Thyroid stimulating hormone

Diagnostic Codes: 244 (Hypothyroidism), 242 (Hyperthyroidism)

Appendices

• Appendix 1: BC Laboratory Algorithm for Thyroid Tests

This guideline is based on scientific evidence current as of the effective date.

The guideline was developed by the Guidelines and Protocols Advisory Committee in collaboration with BC’s Agency for Pathology and Laboratory Medicine and adopted by the Medical Services Commission.
Appendix 1: BC Laboratory Algorithm for Thyroid Tests

For a clinical algorithm, see guideline Figure 1: Clinical Algorithm for Thyroid Function Tests for Diagnosis and Monitoring in Symptomatic Non-Pregnant Patients. Upper limit of normal = ULN.

*Specific Clinical Indications
- Suspicion of “pituitary” insufficiency
- “Thyrotoxicosis”
- Patient age < 1 year at time of sample collection
- Previous TSH inconsistent with patient presentation†
- Query analytical interference†
† Requires consultation with laboratory physician

TSH ordered with fT4 and/or fT3

Measure TSH

≥10 mU/L

Measure fT4

Normal

Abnormal

Cancel fT3 if ordered

Report TSH, fT4 and fT3

ULN-10 mU/L

Measure fT4

Cancel fT3 if ordered

Report TSH and fT4

Low

Does a specific clinical indication apply?*

Yes

Measure fT4 and fT3

Report TSH, fT4 and fT3

No

Cancel fT4 and/or fT3

Report TSH

High

Report fT4 and/or fT3

fT4 and/or fT3 ordered without other thyroid test

Does a specific clinical indication apply?*

Yes

Measure fT4 and/or fT3

Report fT4 and/or fT3

No

Cancel fT4 and fT3